Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 936 trials

Advanced Cancer: SOT201 Treatment Study

We are evaluating the safety and effectiveness of SOT201 in patients with advanced or metastatic cancer. This study aims to see how well this treatment works compared to current options.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Prostate Cancer: AMG 509 Treatment Study

We are testing a new drug called AMG 509 for men with metastatic castration-resistant prostate cancer. The study aims to evaluate its safety and how it may help manage this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Oncology

Advanced MTAP-null Solid Tumors: AMG 193 Treatment Study

We are studying the safety and effectiveness of AMG 193, both alone and with docetaxel, for adults with advanced MTAP-null solid tumors. This research aims to find better treatment options for these patients.

Advanced MTAP-null Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatologyOncology

Retinitis Pigmentosa: New Treatment Trial

We are investigating a new treatment for patients with retinitis pigmentosa. The goal is to see if it can help improve vision or slow down vision loss.

Retinitis PigmentosaSafety phase (I)Efficacy phase (II)Ophthalmology

Traumatic Brain Injury: Wharton's Jelly Stem Cells

We are investigating whether stem cells from umbilical cord tissue can help reduce inflammation and improve immune response after a traumatic brain injury. This study aims to find new treatment options for recovery.

Severe Traumatic Brain Injury (TBI)>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

GTX-11: Safety Study in Healthy Volunteers

We are testing a new medication called GTX-11 to see how safe it is and how the body handles it. Healthy adults are participating to help us understand its effects.

Pulmonary Fibrosis1-2 yearsSafety phase (I)Pulmonology

SENS-501 for Children with Hearing Loss from Otoferlin Mutations

We are studying a new injection treatment for children with severe to profound hearing loss due to Otoferlin gene mutations. The trial will assess both the safety and effectiveness of this treatment.

Bilateral Severe to Profound Hearing LossSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOtolaryngology

Stomach and Pancreatic Cancer: ASP2138 Treatment Study

We are investigating the effects of ASP2138 alone and with other cancer treatments for adults with stomach, gastroesophageal junction, or pancreatic cancer. This study aims to see if it can improve treatment results.

Pancreatic CancerStomach CancerGastroesophageal Junction Cancer>2 yearsSafety phase (I)Oncology

Colorectal Liver Metastases: IP-001 Immuno-Adjuvant Study

We are exploring a new treatment to see if it improves outcomes for patients with colorectal liver metastases after microwave ablation or electroporation. The study will help us understand the best dose and immune response.

Colorectal Liver Metastases>2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyHepatologyInternal MedicineOncology

Hereditary Haemochromatosis: NNC0614-0001 Study

We are evaluating the effects of a new treatment in healthy adults and individuals with hereditary haemochromatosis type 1. This research aims to understand how the treatment works in these groups.

Hereditary Hemochromatosis>2 yearsSafety phase (I)HematologyInternal Medicine

COVID-19 Vaccine Booster Study: CD40.RBDv

We are testing a new bivalent COVID-19 vaccine to see if it safely boosts immunity in volunteers. This study will help us understand its effectiveness compared to existing vaccines.

COVID-19>2 yearsSafety phase (I)Infectious Diseases

Advanced Solid Tumors: IPH5301 Treatment Study

We are exploring a new treatment called IPH5301, both alone and with chemotherapy and trastuzumab, for patients with advanced solid tumors. This study aims to understand how well it works and its safety in humans.

Advanced and Metastatic Cancer>2 yearsSafety phase (I)Oncology

Multiple Myeloma: ABBV-383 Treatment Study

We are evaluating the safety and optimal dosing of ABBV-383 for individuals with relapsed or refractory multiple myeloma. This study aims to improve treatment options for this challenging condition.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Oncology

Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia

We are studying a new treatment for children with relapsed or refractory Acute Lymphoblastic Leukemia to see how well it works and how safe it is. This trial includes both single-agent and combination therapy approaches.

Recurrent Pediatric Acute Lymphoblastic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Advanced Solid Tumors: RO7502175 Treatment Study

We are evaluating a new treatment for patients with locally advanced or metastatic solid tumors. The study looks at its safety and effectiveness alone and with another cancer therapy.

Locally Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Advanced Solid Tumors: STX-478 Treatment Study

We are investigating the effects of STX-478 alone and with other cancer drugs for people with advanced solid tumors. This study aims to see how well these treatments work together.

Breast CancerAdvanced Solid TumorsHead and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Advanced Solid Tumors: Debio 0123 Treatment

We are evaluating the safety and early anti-tumor effects of Debio 0123 in adults with advanced solid tumors. This study aims to see how well this treatment works compared to existing options.

Ovarian Epithelial CancerUterine CarcinomaSolid Tumor>2 yearsSafety phase (I)Oncology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology